Figure 2.
TGF-β signaling-targeted antitumor agents. At present, TGF-β signaling has been a hot therapeutic target for cancer investigators, and enormous efforts have been expended on the development of TGF-β-targeted agents. (A) TGF-β blockade strategies, including monoclonal antibodies (containing bispecific antibodies), ligand traps (containing bi-functional proteins), receptor kinase inhibitors, vaccines, and antisense oligonucleotides, are under clinical evaluation. (B) The structure of fusion protein M7824. (C) The structure of bispecific antibody YM101.